A new study published on the website of Nutrition, Metabolism & Cardiovascular Diseases represents the first published human study to positively link resveratrol to the physiological effects of the French Paradox and better cardiovascular health.
A new study published on the website of Nutrition, Metabolism & Cardiovascular Diseases represents the first published human study to positively link resveratrol to the physiological effects of the French Paradox and better cardiovascular health.
The study, conducted by Dr. Peter Howe at the University of South Australia, demonstrates that DSM’s resVida resveratrol is effective in improving flow mediated dilation (FMD) in humans. FMD is a bio-marker linked to the healthy functioning of the cardiovascular system.
(See the company’s website for details about how the study was conducted.) resVida is a 99% pure, nature-identical form of trans-resveratrol. The dietary ingredient is supported by a full safety package.
Resveratrol, one of the most physiologically active compounds in red wine, (and red wine consumption in general) has been thought to be responsible for the French Paradox--the phenomenon that French people, although consuming a diet high in fat, enjoy robust cardiovascular health and a low cardiovascular mortality rate when compared to other Western countries.
DSM is involved with five ongoing human studies for resVida. The company was a contributing sponsor and presenter at Resveratrol2010, the first International Scientific Conference of Resveratrol and Health in Copenhagen, Denmark.
DSM
011 +41 (0) 61 815 83 54
www.resVida.com
